SCHEMBL8087262

SCHEMBL8087262

Cc1cc(OC2CCN(Cc3ccccc3F)C(C)C2)c2ccccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 1/20 0.39
CHRM4 P08173 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
PDE2A O00408 1/20 0.37
NCF1 P14598 3/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
PDE4B Q07343 1/20 0.37
SCN1A P35498 2/20 0.37
SCN8A Q9UQD0 2/20 0.37
HTT P42858 2/20 0.37
EHMT2 Q96KQ7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4243998 0.90 JAK2 (0.37) HCRTR2MEN1KMT2AKDM4EJAK2
SCHEMBL13945426 0.86 MEN1 (0.43) HCRTR1HCRTR2MEN1KMT2AKDM4E
SCHEMBL5529538 0.85 PDE4B (0.46) MEN1KMT2AKDM4ERAB9APDE2A
SCHEMBL8095680 0.74 PDE4B (0.46) MEN1KMT2AKDM4EPDE2APDE4B
SCHEMBL14437478 0.74 NCF1 (0.44) HCRTR1HCRTR2KDM4ERAB9ANCF1
SCHEMBL23377490 0.73 HCRTR2 (0.38) HCRTR1HCRTR2KDM4ENCF1ADRB2
SCHEMBL13945374 0.73 DCPS (0.60) EHMT2DCPSHTR1AHTR1DHTR1B
SCHEMBL5528217 0.73 HRH3 (0.52) HCRTR1HCRTR2KMT2AKDM4ECHRM4
SCHEMBL5529129 0.73 HTR1D (0.52) NCF1SCN1ASCN8AHTR1AHTR1D
SCHEMBL5532963 0.73 NCF1 (0.58) NCF1EHMT2MAOBHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 HCRTR1 1111/4885HCRTR2 515/4885MEN1 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.